Newsletter Tool

The top 10 highest-paid medtech CEOs

Today's Rundown

Democrats reach deal on drug pricing reform that caps costs, negotiates Part D and B prices
Moderna finally cracks into gene editing with Metagenomi pact thanks to 'irresistible' data
The top 10 highest-paid medtech CEOs
Once sidelined, Eli Lilly's COVID-19 antibody treatment is on the comeback trail with new $1.3B supply agreement
Sage tweaks primary endpoint for zuranolone depression trial, leaving key durability question unanswered
ACA coverage less affordable over time for middle-class families, study finds
GV-backed Cambridge Epigenetix lines up $88M to roll out genetic sequencing technology
In the CDMO industry's expansion blitz, Samsung Biologics goes full speed ahead with 'Super Plant,' plans to grow global footprint
Pfizer sells midphase inflammatory drugs to mystery startup, exiting race against Bristol Myers
3D-printed braces maker LightForce Orthodontics sinks teeth into $50M funding round
Novartis makes protein degrader play, inking deal with new British startup to access fruits of novel tech
Lower volumes, higher wages, supply chain disruption all dragged down hospital
Biolinq amasses $100M for its painless glucose sensor patch

Featured Story

Democrats reach deal on drug pricing reform that caps costs, negotiates Part D and B prices

By Robert King

Congressional Democrats reached a deal on drug pricing reform that would cap out-of-pocket costs for seniors and enable Medicare to negotiate for lower drug prices for certain products.

Moderna finally cracks into gene editing with Metagenomi pact thanks to 'irresistible' data

By Annalee Armstrong

We finally know who Moderna has been courting behind the scenes to make the big jump into gene editing. The famed biotech has signed a research partnership with CRISPR gene editing company Metagenomi.

The top 10 highest-paid medtech CEOs

By Conor Hale,Andrea Park

The COVID-19 pandemic presented a once-in-a-generation challenge for the medtech industry, and many of the CEOs on this list met it head-on.

Once sidelined, Eli Lilly's COVID-19 antibody treatment is on the comeback trail with new $1.3B supply agreement

By Kevin Dunleavy

With Eli Lilly's COVID-19 antibody combo once again sanctioned for use in all 50 states, the company reported a new supply deal with the United States. Lilly will supply 614,000 doses of the treatment by the end of January of next year. Lilly's antibodies were sidelined by the FDA from June to August because of their ineffectiveness against certain variants.

Sage tweaks primary endpoint for zuranolone depression trial, leaving key durability question unanswered

By Annalee Armstrong

Sage Therapeutics has slightly tweaked the primary endpoint for a phase 3 trial of the Biogen-partnered depression drug zuranolone, a move analysts say is likely designed to avoid a miss on the original goal and one that could complicate the drug's real-world use.

ACA coverage less affordable over time for middle-class families, study finds

By Robert King

Affordable Care Act insurance exchange coverage got increasingly unaffordable for middle-class families that don't qualify for income-based tax credits, a new study found.

GV-backed Cambridge Epigenetix lines up $88M to roll out genetic sequencing technology

By Andrea Park

With the additional funds, the University of Cambridge spinout will accelerate the commercialization of its sequencing platform. It’ll also ramp up manufacturing of the first product built on the platform, which the company said is expected to be commercially available by early next year.

In the CDMO industry's expansion blitz, Samsung Biologics goes full speed ahead with 'Super Plant,' plans to grow global footprint

By Kevin Dunleavy

Since it was established in 2011 and in short order became a CDMO force, Samsung Biologics has sought to do everything quickly. Now, in the biopharma manufacturing industry’s rush for expansion, few companies are as equipped for the sprint like Samsung.

Pfizer sells midphase inflammatory drugs to mystery startup, exiting race against Bristol Myers

By Nick Paul Taylor

Pfizer is getting out of TYK2. Having studied its lead inhibitor in a raft of inflammatory diseases, the Big Pharma is offloading the portfolio to a new company in return for a 25% stake in the startup.

3D-printed braces maker LightForce Orthodontics sinks teeth into $50M funding round

By Andrea Park

LightForce's system combines 3D printing technology and cloud-based treatment planning software to produce braces fully customized to each patient’s teeth and orthodontic needs.

Novartis makes protein degrader play, inking deal with new British startup to access fruits of novel tech

By Nick Paul Taylor

The search for an edge in the hot protein degrader space has led Novartis to Dunad Therapeutics. By putting up $24 million and committing to $1.3 billion in biobucks, Novartis has secured the chance to option candidates against up to four targets worked on by its new partner.

Lower volumes, higher wages, supply chain disruption all dragged down hospital

By Dave Muoio

Monthly hospital data from Kaufman Hall outlined monthly declines across "almost every metric" and evidence that consumers are again wary of seeking outpatient care.

Biolinq amasses $100M for its painless glucose sensor patch

By Conor Hale

The race for the next major advancement in diabetes tracking technology continues to heat up, with Biolinq securing a hefty $100 million in investor support to kick-start the development of its wearable, noninvasive glucose sensor patch.

PM Tracker

Featured Story

Democrats reach deal on drug pricing reform that caps costs, negotiates Part D and B prices

Top Stories

Moderna finally cracks into gene editing with Metagenomi pact thanks to 'irresistible' data

The top 10 highest-paid medtech CEOs

Once sidelined, Eli Lilly's COVID-19 antibody treatment is on the comeback trail with new $1.3B supply agreement

Sage tweaks primary endpoint for zuranolone depression trial, leaving key durability question unanswered

ACA coverage less affordable over time for middle-class families, study finds

GV-backed Cambridge Epigenetix lines up $88M to roll out genetic sequencing technology

In the CDMO industry's expansion blitz, Samsung Biologics goes full speed ahead with 'Super Plant,' plans to grow global footprint

Pfizer sells midphase inflammatory drugs to mystery startup, exiting race against Bristol Myers

3D-printed braces maker LightForce Orthodontics sinks teeth into $50M funding round

Novartis makes protein degrader play, inking deal with new British startup to access fruits of novel tech

Lower volumes, higher wages, supply chain disruption all dragged down hospital

Biolinq amasses $100M for its painless glucose sensor patch